BioAge Labs, Inc. (NASDAQ:BIOA) Stock Has Average Price Target of $36.57

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $36.57.

BIOA has been the subject of a number of recent analyst reports. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a report on Friday, July 31st. Roth Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a report on Wednesday, September 9th. Needham & Company LLC lowered their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of BioAge Labs in a research note on Tuesday, September 8th. Finally, Wall Street Zen upgraded BioAge Labs from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 13th.

BioAge Labs Stock Down 0.7%

BioAge Labs stock opened at $7.09 on Thursday. The business’s 50-day moving average price is $10.92 and its 200 day moving average price is $16.21. The firm has a market cap of $325.43 million, a price-to-earnings ratio of -2.98 and a beta of 0.94. BioAge Labs has a 52 week low of $5.04 and a 52 week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The business had revenue of $2.45 million for the quarter. Equities analysts expect that BioAge Labs will post -2.45 EPS for the current year.

Institutional Trading of BioAge Labs

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of BioAge Labs during the 2nd quarter worth approximately $69,831,000. Jupiter Topco LLC acquired a new stake in shares of BioAge Labs in the second quarter valued at approximately $52,597,000. Janus Henderson Group PLC increased its holdings in shares of BioAge Labs by 411.8% in the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after purchasing an additional 1,685,063 shares during the last quarter. Octagon Capital Advisors LP lifted its position in BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after buying an additional 150,000 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in BioAge Labs during the second quarter worth approximately $8,686,000.

About BioAge Labs

BioAge Labs, Inc (NASDAQ:BIOA) is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. Its research uses human longevity data and proprietary computational biology tools to identify pathways associated with aging-related diseases and to develop potential therapies aimed at extending healthy lifespan and improving physical function.

The company’s lead investigational program is azelaprag, also known as BGE-105, an oral small-molecule apelin receptor agonist being studied for its potential to preserve muscle mass and improve physical performance in older adults.